Department of Pharmacy, Barnes‐Jewish Hospital, St. Louis, Missouri
Vancomycin remains the reference standard for the treatment of systemic infection caused by methicillin‐resistant Staphylococcus aureus (MRSA). However, as a result of limited tissue distribution, as well as the emergence of isolates with reduced susceptibility and in vitro resistance to vancomycin, the need for alternative therapies that target MRSA has become apparent. New treatment options for invasive MRSA infections include linezolid, daptomycin, tigecycline, and quinupristin/dalfopristin. Additionally, a number of new anti‐MRSA compounds are in development, including novel glycopeptides (dalbavancin, telavancin, and oritavancin), ceftobiprole, and iclaprim. The present article will review clinical issues surrounding the newly marketed and investigational agents with activity against MRSA.
Cited by
Hee‐Chang Jang, Sung‐Han Kim, Kye Hyoung Kim, Choong Jong Kim, Shinwon Lee, Kyoung‐Ho Song, Jae Hyun Jeon, Wan Beom Park, Hong Bin Kim, Sang‐Won Park, Nam Joong Kim, Eui‐Chong Kim, Myoung‐don Oh, and Kang Won Choe. (2009) Salvage Treatment for Persistent Methicillin‐Resistant
Staphylococcus aureus Bacteremia: Efficacy of Linezolid With or Without Carbapenem.
Clinical Infectious Diseases 49:3, 395-401
Online publication date: 1-Aug-2009.
, O. Gallon, C. Guillet-Caruba, B. Lamy, F. Laurent, F. Doucet-Populaire, J.-W. Decousser. (2009) In vitro activity of daptomycin against Staphylococci isolated from bacteremia and community-onset skin and soft tissue infections in France: data from two nationwide studies.
European Journal of Clinical Microbiology & Infectious Diseases Online publication date: 6-Jul-2009.
CrossRef Amy M. Creel, Spencer H. Durham, Kim W. Benner, Jeffrey A. Alten, Margaret K. Winkler. (2009) Severe invasive community-associated methicillin-resistant Staphylococcus aureus infections in previously healthy children *.
Pediatric Critical Care Medicine 10:3, 323-327
Online publication date: 1-Jun-2009.
CrossRef Kenneth V. I. Rolston. (2009) New antimicrobial agents for the treatment of bacterial infections in cancer patients.
Hematological Oncology n/a-n/a
Online publication date: 1-Feb-2009.
CrossRef Knut Ohlsen, Gudrun Dandekar, Roland Schwarz, Thomas Dandekar. (2008) New trends in pharmacogenomic strategies against resistance development in microbial infections.
Pharmacogenomics 9:11, 1711-1723
Online publication date: 1-Dec-2008.
CrossRef Lena M. Napolitano. (2008) Early Appropriate Parenteral Antimicrobial Treatment of Complicated Skin and Soft Tissue Infections Caused by Methicillin-Resistant
Staphylococcus aureus.
Surgical Infections 9:s1, s17-s27
Online publication date: 1-Nov-2008.
CrossRef Natasha VDV Ratnaraja, Peter M Hawkey. (2008) Current challenges in treating MRSA: what are the options?.
Expert Review of Anti-infective Therapy 6:5, 601-618
Online publication date: 1-Nov-2008.
CrossRef G. Fritsche, G. Weiss. (2008) Therapeutic options for the treatment of infections with multiresistant grampositive bacteria in oncological patients.
memo - Magazine of European Medical Oncology 1:3, 177-180
Online publication date: 1-Oct-2008.
CrossRef Andreas M Lenz, Mark Fairweather, William G Cheadle. (2008) Resistance profiles in surgical-site infection.
Future Microbiology 3:4, 453-462
Online publication date: 1-Sep-2008.
CrossRef AJ O'Neill. (2008) New antibacterial agents for treating infections caused by multi-drug resistant Gram-negative bacteria.
Expert Opinion on Investigational Drugs 17:3, 297-302
Online publication date: 1-Apr-2008.
CrossRef Andreas F. Widmer. (2008)
Editorial Commentary: Ceftobiprole: A New Option for Treatment of Skin and Soft‐Tissue Infections due to Methicillin‐Resistant
Staphylococcus aureus.
Clinical Infectious Diseases 46:5, 656-658
Online publication date: 1-Mar-2008.
Garyphallia Poulakou, Helen Giamarellou. (2008) Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.
Expert Opinion on Investigational Drugs 17:2, 225-243
Online publication date: 1-Mar-2008.
CrossRef